RxDoctor Payments Data

Reema Abou Nasr, MD

Family Medicine · Omaha, NENPI 1366553224

Payments from drug & device makers

$4,350in general payments, 2019–2025

Across 259 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$943
  • Novo Nordisk$592
  • Lilly USA, LLC$475
  • Pfizer$322
  • GSK$279
  • Biohaven Pharmaceutical Holding Company Ltd.$192
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,350 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$133,572
Medicare patients
204
Services billed
7,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$128,902
JanuviaSitagliptin Phosphate47$40,607
MounjaroTirzepatide37$39,436
JardianceEmpagliflozin38$35,599
EliquisApixaban24$21,047
Breo ElliptaFluticasone/Vilanterol37$19,917
LinzessLinaclotide18$18,505
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$7,937
Emgality SyringeGalcanezumab-Gnlm11$7,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,504
Celecoxib83$5,197
Gabapentin186$3,705
SymbicortBudesonide/Formoterol Fumarate17$3,651
Omeprazole246$3,476
Bupropion XlBupropion Hcl101$2,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$592$128,902113 claims
MerckJanuvia$60$40,60747 claims
Lilly USA, LLCMounjaro$475$39,43637 claims
Boehringer IngelheimJardiance$32$35,59938 claims
GSKBreo Ellipta, Trelegy Ellipta$279$27,42149 claims
PfizerEliquis$322$21,04724 claims
AbbVieLinzess, Synthroid$943$19,20136 claims
AstraZenecaSymbicort$105$3,65117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →